On November 16, the Juveàcell Launch Symposium took place at the Vista Walkerhill Hotel in Seoul, drawing strong attendance from clinicians despite being held on a Sunday morning. In Chairing Session 1, Dr. Kyle Seo (Modelo Dermatology) predicted that, from 2025, human acellular dermal matrix (hADM) injectables will set a new trend, noting hADM as a material optimized for regeneration. Yongwoo Shin, CEO of DOF Co., Ltd., introduced Juveàcell as an hADM injectable processed with supercritical CO₂ decellularization, which preserves ECM architecture while minimizing residual toxicity—technology already validated in over 38,000 clinical uses. Dr. Jongseo Kim (Kim Jongseo Plastic Surgery) discussed the synergy between JuveLook and Juveàcell. In the panel discussion moderated by Dr. Hongseok Kim (VOS Dermatology), Dr. Arim Min (MIN & MIN Clinic), Dr. Hyohyun Seok (AllLiting Plastic Surgery), Dr. Dongwoo Shin (NAVI Plastic Surgery), and Dr. Hyoseung Jang (Pieobom Clinic, Gangnam) shared practical cases on neck lines, periocular improvement, safety, and procedural convenience. Attendees expressed high expectations for Juveàcell as a product poised to open a new category in regenerative aesthetic medicine.
#MedicalAestheticNews #VAIM #Juveàcell #hADM #JUVELOOK #PDLLA
★ Article Link: https://www.aestheticnews.co.kr/news/articleView.html?idxno=10996
_Eng%231.jpg)
_Eng%232.jpg)
_Eng%233.jpg)
_Eng%234.jpg)
_Eng%235.jpg)
_Eng%236.jpg)
_Eng%237.jpg)
Comments
Post a Comment